<DOC>
	<DOCNO>NCT00359879</DOCNO>
	<brief_summary>This trial design compare effect twice-daily ( lunch dinner ) exenatide plus oral antidiabetic ( OAD ) agents twice-daily ( breakfast dinner ) exenatide plus OAD respect glycemic control ( HbA1c ) patient type 2 diabetes .</brief_summary>
	<brief_title>Comparison Exenatide Taken Before Lunch Dinner With Before Breakfast Dinner Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Diagnosed type 2 diabetes . Have treat one follow treatment regimen least three month prior screen : *metformin alone ; *sulfonylurea ( SU ) alone ; *thiazolidinedione ( TZD ) alone ; *a combination metformin SU ; *a combination metformin TZD . HbA1c 7.1 % 10.0 % , inclusive . Body Mass Index ( BMI ) &gt; 25 kg/m^2 &lt; 45 kg/m^2 Have participate interventional , medical , surgical , pharmaceutical study ( study experimental drug , medical , surgical treatment give ) within 30 day prior screen . Have characteristic contraindicate metformin , SU , TZD use . Are receive chronic ( lasting longer 2 week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive therapy within 2 week immediately prior screening . Have use prescription drug promote weight loss within 3 month prior screen . Are currently treat ( great 2 consecutive week ) follow excluded medication : *insulin within 3 month prior screen ; *alphaglucosidase inhibitor within 3 month prior screen ; *meglitinides within 3 month prior screen ; *drugs directly affect gastrointestinal motility</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>Lilly</keyword>
	<keyword>Amylin</keyword>
</DOC>